SCHEMBL3479668

SCHEMBL3479668

CN1CCN(c2ccccc2F)c2ccc(-c3ccc(CO)nn3)cc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.41
NOTUM Q6P988 1/20 0.38
SLC6A2 P23975 4/20 0.34
SLC6A4 P31645 4/20 0.34
SLC6A3 Q01959 1/20 0.34
SCD O00767 2/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
CHRM1 P11229 1/20 0.31
ADRA1D P25100 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479675 0.88 SCN9A (0.39) SCN9ANOTUMSLC6A2SLC6A4SLC6A3
SCHEMBL3230636 0.87 SCN9A (0.46) SCN9ANOTUMSLC6A2SLC6A4SLC6A3
SCHEMBL3221417 0.86 SCN9A (0.40) SCN9ANOTUMSLC6A2SLC6A4SLC6A3
SCHEMBL3222271 0.85 SLC6A2 (0.47) SCN9ASLC6A2SLC6A4SLC6A3MEN1
SCHEMBL3231884 0.85 SCN9A (0.41) SCN9ASLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL3479995 0.85 SCN9A (0.44) SCN9ASLC6A2SLC6A4SLC6A3SCD
SCHEMBL3228259 0.85 SCN9A (0.47) SCN9ASCDALDH1A1
SCHEMBL3479601 0.85 SCN9A (0.43) SCN9ANOTUMSLC6A2SLC6A4SLC6A3
SCHEMBL3217112 0.85 SCN9A (0.40) SCN9ASLC6A2SLC6A4SLC6A3NPC1
SCHEMBL3479579 0.84 SCN9A (0.45) SCN9ANOTUMSLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885NOTUM 3324/4885SLC6A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.